CoChat

Glutathione-responsive and -exhausting metal nanomedicines for robust synergistic cancer therapy

Open access
Liu, Peng, Hao, Lu, Liu, Min, Hu, Shuo · 2023 · Frontiers in Bioengineering and Biotechnology

The DOI matches its Crossref record; 95 of the 95 references it cites were found in a registry or an index.

Abstract

Due to their rapid and uncontrolled proliferation, cancer cells are characterized by overexpression of glutathione (GSH), which impairs reactive oxygen species (ROS)-based therapy and weakens the chemotherapeutic agent-induced toxification. Extensive efforts have been made in the past few years to improve therapeutic outcomes by depleting intracellular GSH. Special focus has been given to the anticancer applications of varieties of metal nanomedicines with GSH responsiveness and exhaustion capacity. In this review, we introduce several GSH-responsive and -exhausting metal nanomedicines that can specifically ablate tumors based on the high concentration of intracellular GSH in cancer cells. These include inorganic nanomaterials, metal-organic frameworks (MOFs), and platinum-based nanomaterials. We then discuss in detail the metal nanomedicines that have been extensively applied in synergistic cancer therapy, including chemotherapy, photodynamic therapy (PDT), sonodynamic therapy (SDT), chemodynamic therapy (CDT), ferroptotic therapy, and radiotherapy. Finally, we present the horizons and challenges in the field for future development.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fbioe.2023.1161472

Cites

95 of 95 references verified0 citation errors · 0 not checkable

Statistics

Figures

SCHEME 1 An overview of GSH-responsive and -exhausting metal nanomedicines for synergistic cancer therapy.
SCHEME 1 An overview of GSH-responsive and -exhausting metal nanomedicines for synergistic cancer therapy.CC BY · PubMed Central
FIGURE 1 (A) Michaelis-Menten kinetics and (B) Lineweaver-Burk curves for Pd SAzyme with GSH as a substrate. (C) The Km and Vmax of as prepared Pd SAzyme, Cu2-xTe, and SSNEs with GSH as the substrate for GSH peroxidase catalysis. Reproduced with permission. Copyright 2021 John Wiley & Sons. (D) The mechanism of MnO2 for Fenton metal ion delivery and GSH exhaustion. (E) Photo of MnO2-MSNs after incubating with different concentrations of GSH. (F) The GSH level of U87MG cells after the incubation with MnO2-MSNs. (G) Release behavior of CPT from GSH-treated MnO2-MSNs. Reproduced with permission. Copyright 2018 John Wiley & Sons. (H) Schematic illustration of the H2O2/GSH-responsive TeNWs for selective cancer therapy. (I) Histogram of the ratio of GSSH/GSH in MCF-7 and Hela cells after being treated with TeNWs. (J) Anticancer activity of TeNWs against cancer cells (Hela, A549, MCF-7) and normal cells (HSF, L02). Reproduced with permission. Copyright 2019 Royal Society of Chemistry.
FIGURE 1 (A) Michaelis-Menten kinetics and (B) Lineweaver-Burk curves for Pd SAzyme with GSH as a substrate. (C) The Km and Vmax of as prepared Pd SAzyme, Cu2-xTe, and SSNEs with GSH as the substrate for GSH peroxidase catalysis. Reproduced with permission. Copyright 2021 John Wiley & Sons. (D) The mechanism of MnO2 for Fenton metal ion delivery and GSH exhaustion. (E) Photo of MnO2-MSNs after incubating with different concentrations of GSH. (F) The GSH level of U87MG cells after the incubation with MnO2-MSNs. (G) Release behavior of CPT from GSH-treated MnO2-MSNs. Reproduced with permission. Copyright 2018 John Wiley & Sons. (H) Schematic illustration of the H2O2/GSH-responsive TeNWs for selective cancer therapy. (I) Histogram of the ratio of GSSH/GSH in MCF-7 and Hela cells after being treated with TeNWs. (J) Anticancer activity of TeNWs against cancer cells (Hela, A549, MCF-7) and normal cells (HSF, L02). Reproduced with permission. Copyright 2019 Royal Society of Chemistry.CC BY · PubMed Central
FIGURE 2 (A) Schematic illustration of FT@HA synthesis. (B) The pH and GSH-responsive TCPP release. (C) Detection of GSH consumption. Reproduced with permission. Copyright 2020 American Chemical Society. (D) The scheme of Mn3+-TCPP MOFs preparation and mechanism for redox-unlocked therapy. (E) Scanning electron microscope images of Mn3+-TCPP MOFs with various concentrations of GSH. Reproduced with permission. Copyright 2019 American Chemical Society. (F) Schematic illustration of Fe(II)-BNCP preparation and NO-CDT synergistic therapy. (G) NO release from Fe(II)-BNCP at various levels of GSH. (H) The mechanism of NO release from Fe(II)-BNCP in high levels of GSH. Reproduced with permission. Copyright 2019 American Chemical Society.
FIGURE 2 (A) Schematic illustration of FT@HA synthesis. (B) The pH and GSH-responsive TCPP release. (C) Detection of GSH consumption. Reproduced with permission. Copyright 2020 American Chemical Society. (D) The scheme of Mn3+-TCPP MOFs preparation and mechanism for redox-unlocked therapy. (E) Scanning electron microscope images of Mn3+-TCPP MOFs with various concentrations of GSH. Reproduced with permission. Copyright 2019 American Chemical Society. (F) Schematic illustration of Fe(II)-BNCP preparation and NO-CDT synergistic therapy. (G) NO release from Fe(II)-BNCP at various levels of GSH. (H) The mechanism of NO release from Fe(II)-BNCP in high levels of GSH. Reproduced with permission. Copyright 2019 American Chemical Society.CC BY · PubMed Central
FIGURE 3 (A) Illustration showing GSH consumption induced Fe3+ and active cisplatin release, and ROS-mediated DNA damage. (B) The GSH and GSSH contents in C6 cells after performing various treatments. (C) The cisplatin release behavior and transmission electron microscope image of various nanoscale coordination polymers after treatment with GSH. Reproduced with permission. Copyright 2020 American Chemical Society. (D) Schematic illustration of ONOO− generation by SPNA for enhanced Pt-based chemotherapy. (E) Pt and (F) NO release behaviors of SPNA in PBS with or without ASA/GSH (ASA is a reductive substance similar to GSH). Reproduced with permission. Copyright 2021 American Chemical Society.
FIGURE 3 (A) Illustration showing GSH consumption induced Fe3+ and active cisplatin release, and ROS-mediated DNA damage. (B) The GSH and GSSH contents in C6 cells after performing various treatments. (C) The cisplatin release behavior and transmission electron microscope image of various nanoscale coordination polymers after treatment with GSH. Reproduced with permission. Copyright 2020 American Chemical Society. (D) Schematic illustration of ONOO− generation by SPNA for enhanced Pt-based chemotherapy. (E) Pt and (F) NO release behaviors of SPNA in PBS with or without ASA/GSH (ASA is a reductive substance similar to GSH). Reproduced with permission. Copyright 2021 American Chemical Society.CC BY · PubMed Central
FIGURE 4 (A) Schematic illustration of GSH consuming-sensitized chemotherapy. (B) The capability of depleting GSH with CuMOF@Pt (IV) using 5, 5′-dithio-bis-2-(nitrobenzoic acid) (DTNB) as an indicator. Reproduced with permission. Copyright 2021 Elsevier. (C) DFMC was decomposed in an acidic environment and GSH was oxidized to GSSG via reacting with Mn4+/Mn3+/Fe3+. (D) Release state of Mn ions in the presence or absence of GSH with different pHs. (E) The level of GSH in CT26 cancer cells and (F) tumor tissue in the treatment of PBS, CB-839, DFM (DFMC without CB-839) and DFMC groups. Reproduced with permission. Copyright 2022 American Chemical Society.
FIGURE 4 (A) Schematic illustration of GSH consuming-sensitized chemotherapy. (B) The capability of depleting GSH with CuMOF@Pt (IV) using 5, 5′-dithio-bis-2-(nitrobenzoic acid) (DTNB) as an indicator. Reproduced with permission. Copyright 2021 Elsevier. (C) DFMC was decomposed in an acidic environment and GSH was oxidized to GSSG via reacting with Mn4+/Mn3+/Fe3+. (D) Release state of Mn ions in the presence or absence of GSH with different pHs. (E) The level of GSH in CT26 cancer cells and (F) tumor tissue in the treatment of PBS, CB-839, DFM (DFMC without CB-839) and DFMC groups. Reproduced with permission. Copyright 2022 American Chemical Society.CC BY · PubMed Central
FIGURE 5 (A) Investigation of the capacity of CCF with different concentrations to exhaust GSH at different time points. (B) Variations of GSH fluorescence intensity and 4T1 cells survival status after co-culture of CCF and 4T1 cells in different concentrations. Reproduced with permission. Copyright 2021 John Wiley & Sons. (C) The schematic illustration of DHA@MIL-101 NRs prompting CDT-ferroptotic cancer therapy through inactivating GPX4 directly or indirectly. (D) Comparison of GSH content in Lewis cells after incubation with DHA, MIL-101 NRs, and DHA@MIL-101 NRs. (E) The morphology of mitochondria (main characteristic of ferroptosis) when treated with DHA@MIL-101 NRs using TEM. Reproduced with permission. Copyright 2022 BioMed Central. (F) Schematic diagram of ferroptosis generated by GSH-deletion mediated GPX4 inactivity. (G) Examining GSH depletion capacity of PBS, Mn-TCPP, MOF, and Mn-MOF with different concentrations of Zr. (H) Alterations of intracellular GSH content and (I) GPX4 activity after treatment of H22 cells with PBS, Mn-TCPP, MOF, and Mn-MOF respectively. Reproduced with permission. Copyright 2021 Ivyspring International Publisher.
FIGURE 5 (A) Investigation of the capacity of CCF with different concentrations to exhaust GSH at different time points. (B) Variations of GSH fluorescence intensity and 4T1 cells survival status after co-culture of CCF and 4T1 cells in different concentrations. Reproduced with permission. Copyright 2021 John Wiley & Sons. (C) The schematic illustration of DHA@MIL-101 NRs prompting CDT-ferroptotic cancer therapy through inactivating GPX4 directly or indirectly. (D) Comparison of GSH content in Lewis cells after incubation with DHA, MIL-101 NRs, and DHA@MIL-101 NRs. (E) The morphology of mitochondria (main characteristic of ferroptosis) when treated with DHA@MIL-101 NRs using TEM. Reproduced with permission. Copyright 2022 BioMed Central. (F) Schematic diagram of ferroptosis generated by GSH-deletion mediated GPX4 inactivity. (G) Examining GSH depletion capacity of PBS, Mn-TCPP, MOF, and Mn-MOF with different concentrations of Zr. (H) Alterations of intracellular GSH content and (I) GPX4 activity after treatment of H22 cells with PBS, Mn-TCPP, MOF, and Mn-MOF respectively. Reproduced with permission. Copyright 2021 Ivyspring International Publisher.CC BY · PubMed Central
FIGURE 6 (A) Schematic diagram of Glud-MFo-c degradation in an acidic environment. (B) Hydrogen-nuclear magnetic resonance spectra (1H NMR) of GSH after incubation with Glud-MFo-c at different time points. (C) Comparison of GSH content in confocal images after different treatment of 4T1 cells. Reproduced with permission. Copyright 2020 American Chemical Society. (D) A diagram of GSH depletion mechanism in tumor tissue. (E) The GSH consumption performance of MnWOX-PEG at different time points. (F) Tumor growth of mice after different treatments. Reproduced with permission. Copyright 2019 John Wiley & Sons.
FIGURE 6 (A) Schematic diagram of Glud-MFo-c degradation in an acidic environment. (B) Hydrogen-nuclear magnetic resonance spectra (1H NMR) of GSH after incubation with Glud-MFo-c at different time points. (C) Comparison of GSH content in confocal images after different treatment of 4T1 cells. Reproduced with permission. Copyright 2020 American Chemical Society. (D) A diagram of GSH depletion mechanism in tumor tissue. (E) The GSH consumption performance of MnWOX-PEG at different time points. (F) Tumor growth of mice after different treatments. Reproduced with permission. Copyright 2019 John Wiley & Sons.CC BY · PubMed Central
FIGURE 7 (A) Schematic illustration of GSH exhaustion-enhanced radiotherapy with the introduction of Au NCs@His. (B) GSH content in the cells without and with Au NCs@His treatment. (C) Comparison results of DNA damage molecular (named γ-H2AX) expression degree between Au NCs@His and GSH-Au NCs@His under different doses of radiation. Reproduced with permission. Copyright 2018 American Chemical Society. (D) Amplified effect of PDT, CDT, and SDT through GSH depletion and O2 supplement for multimodal synergistic therapy. (E) GSH depletion ability of UPFB in different incubation time. Reproduced with permission. Copyright 2020 American Chemical Society. (F) The proportion of Fe3+/Fe2+ in the presence or absence of GSH. (G) Different antitumor mechanisms of MS-BSA rely on endogenous and exogenous factors. (H) Mn2+ was released from MS-BSA under reductive and acidic environments. Reproduced with permission. Copyright 2021 Elsevier.
FIGURE 7 (A) Schematic illustration of GSH exhaustion-enhanced radiotherapy with the introduction of Au NCs@His. (B) GSH content in the cells without and with Au NCs@His treatment. (C) Comparison results of DNA damage molecular (named γ-H2AX) expression degree between Au NCs@His and GSH-Au NCs@His under different doses of radiation. Reproduced with permission. Copyright 2018 American Chemical Society. (D) Amplified effect of PDT, CDT, and SDT through GSH depletion and O2 supplement for multimodal synergistic therapy. (E) GSH depletion ability of UPFB in different incubation time. Reproduced with permission. Copyright 2020 American Chemical Society. (F) The proportion of Fe3+/Fe2+ in the presence or absence of GSH. (G) Different antitumor mechanisms of MS-BSA rely on endogenous and exogenous factors. (H) Mn2+ was released from MS-BSA under reductive and acidic environments. Reproduced with permission. Copyright 2021 Elsevier.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 95 references

Cited by

See all 58

Metadata

Authors
Liu, P., Hao, L., Liu, M., & Hu, S.
Affiliations
Central South University (CN)
Corresponding author
  • Liu, Min
  • Hu, Shuo
Venue
Frontiers in Bioengineering and Biotechnology
Published
2023-03-10
Volume
11
Pages
1161472-1161472
ISSN
2296-4185 (ISSN-L)
OpenAlex
W4323857505
Cited by
58
References
95
Citations by year
2026: 20 · 2025: 19 · 2024: 17 · 2023: 2
FWCI
1.30
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Bioengineering and Biotechnology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Natural Science Foundation of China
  • Natural Science Foundation of Hunan Province
  • Science and Technology Program of Hunan Province
Topics
  • Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
  • Physical Sciences › Materials Science › Materials Chemistry › Advanced Nanomaterials in Catalysis
Keywords
glutathione depletion, synergistic cancer therapy, metal-organic frameworks, photodynamic therapy, sonodynamic therapy, chemodynamic therapy, ferroptosis, radiotherapy, reactive oxygen species, chemotherapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Glutathione-responsive and -exhausting metal nanomedicines for robust synergistic cancer therapy. https://app.cochat.ai/papers/10.3389/fbioe.2023.1161472
The paper
Liu, P., Hao, L., Liu, M., & Hu, S. (2023). Glutathione-responsive and -exhausting metal nanomedicines for robust synergistic cancer therapy. Frontiers in Bioengineering and Biotechnology. https://doi.org/10.3389/fbioe.2023.1161472

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.